MCID: SYS070
MIFTS: 35

Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of Childhood

Categories: Blood diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of...

MalaCards integrated aliases for Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of Childhood:

Name: Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of Childhood 12 15
Ebv-Positive T-Cell Lymphoproliferative Disorder of Childhood 12 17
Systemic Ebv-Positive T-Cell Lymphoma of Childhood 12
Lymphoproliferative Disorders 44

Classifications:



External Ids:

Disease Ontology 12 DOID:0070324
MeSH 44 D008232
NCIt 50 C80374
SNOMED-CT 67 450906003
ICD10 32 D47.9

Summaries for Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of...

Disease Ontology : 12 A pediatric lymphoma that is characterized by monoclonal expansion of Epstein-Barr virus-positive T cells with an activated cytotoxic phenotype in tissues or peripheral blood.

MalaCards based summary : Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of Childhood, also known as ebv-positive t-cell lymphoproliferative disorder of childhood, is related to lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. An important gene associated with Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of Childhood is TIA1 (TIA1 Cytotoxic Granule Associated RNA Binding Protein), and among its related pathways/superpathways are NF-kappaB Signaling and Innate Lymphoid Cell Differentiation Pathways. The drugs Hematinics and Epoetin alfa have been mentioned in the context of this disorder. Affiliated tissues include t cells, liver and bone marrow, and related phenotypes are Increased viability with MLN4924 (a NAE inhibitor) and Increased viability with MLN4924 (a NAE inhibitor)

Related Diseases for Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of...

Diseases related to Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of Childhood via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 432)
# Related Disease Score Top Affiliating Genes
1 lymphomatoid papulosis 30.9 TIA1 GZMB
2 primary cutaneous anaplastic large cell lymphoma 30.7 TIA1 GZMB
3 lymphoma, hodgkin, classic 30.6 TIA1 SH2D1A GZMB
4 pancytopenia 30.5 SH2D1A NCAM1 CD2
5 mycosis fungoides 30.5 TIA1 NCAM1 GZMB
6 lymphomatoid granulomatosis 30.4 TIA1 GZMB
7 sezary's disease 30.3 TIA1 NCAM1 CD2
8 hepatosplenic t-cell lymphoma 30.3 TIA1 GZMB
9 peripheral t-cell lymphoma 30.2 TIA1 NCAM1 GZMB
10 orbit lymphoma 30.1 TIA1 NCAM1
11 t-cell lymphoma, subcutaneous panniculitis-like 30.1 TIA1 GZMB
12 reticulosarcoma 30.0 TIA1 GZMB
13 t-cell adult acute lymphocytic leukemia 30.0 TIA1 CD2
14 angioimmunoblastic t-cell lymphoma 30.0 TIA1 GZMB
15 lymphoma, non-hodgkin, familial 29.9 SH2D1A NCAM1 GZMB CR2
16 hemophagocytic lymphohistiocytosis 29.8 SH2D1A GZMB CR2
17 composite lymphoma 29.8 TIA1 GZMB
18 t-cell large granular lymphocyte leukemia 29.8 NCAM1 GZMB
19 panniculitis 29.7 TIA1 NCAM1 GZMB
20 lymphoma 29.6 TIA1 SH2D1A GZMB CR2
21 aggressive nk-cell leukemia 29.4 TIA1 NCAM1 GZMB CD2
22 mature t-cell and nk-cell lymphoma 29.3 TIA1 NCAM1 GZMB CR2 CD2
23 common variable immunodeficiency 29.2 SH2D1A GZMB CR2
24 celiac disease 1 29.1 TIA1 NCAM1 GZMB
25 human immunodeficiency virus infectious disease 29.0 NCAM1 GZMB CR2
26 lethal midline granuloma 28.9 TIA1 NCAM1 GZMB CD2
27 lymphoproliferative syndrome 11.5
28 methotrexate-associated lymphoproliferative disorders 11.3
29 immunodeficiency 75 11.1
30 autoimmune lymphoproliferative syndrome, type v 11.1
31 castleman disease 11.0
32 lymphoid interstitial pneumonia 11.0
33 acquired angioedema 11.0
34 post-transplant lymphoproliferative disease 11.0
35 acquired von willebrand syndrome 11.0
36 granulomatous slack skin disease 11.0
37 immunodeficiency, x-linked, with magnesium defect, epstein-barr virus infection, and neoplasia 11.0
38 necrobiotic xanthogranuloma 11.0
39 unicentric castleman disease 11.0
40 leukemia, chronic lymphocytic 10.9
41 b-cell lymphoma 10.9
42 diffuse large b-cell lymphoma 10.8
43 hairy cell leukemia 10.7
44 mantle cell lymphoma 10.7
45 marginal zone b-cell lymphoma 10.6
46 follicular lymphoma 10.6
47 burkitt lymphoma 10.6
48 hepatitis c virus 10.6
49 immune deficiency disease 10.5
50 leukemia 10.5

Graphical network of the top 20 diseases related to Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of Childhood:



Diseases related to Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of Childhood

Symptoms & Phenotypes for Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of...

GenomeRNAi Phenotypes related to Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of Childhood according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-1 9.5 DDX3X TIA1
2 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-2 9.5 CD2 DDX3X GZMB TIA1
3 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.5 DDX3X
4 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 8.92 CD2 GZMB
5 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 8.92 CD2 GZMB

Drugs & Therapeutics for Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of...

Drugs for Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of Childhood (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 163)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Hematinics Phase 4
2 Epoetin alfa Phase 4 113427-24-0
3
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
4
Perphenazine Approved Phase 3 58-39-9 4748
5
Amitriptyline Approved Phase 3 50-48-6 2160
6
Baclofen Approved Phase 3 1134-47-0 2284
7
Darbepoetin alfa Approved, Investigational Phase 3 209810-58-2, 11096-26-7
8
Pancrelipase Approved, Investigational Phase 3 53608-75-6
9
Everolimus Approved Phase 3 159351-69-6 6442177 70789204
10
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
11
Busulfan Approved, Investigational Phase 2, Phase 3 55-98-1 2478
12
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
13 Ferric Oxide, Saccharated Phase 3
14 Psychotropic Drugs Phase 3
15 Neurotransmitter Agents Phase 3
16 Antipsychotic Agents Phase 3
17 Amitriptyline, perphenazine drug combination Phase 3
18 Excitatory Amino Acid Antagonists Phase 3
19 GABA Agonists Phase 3
20 Antidepressive Agents, Tricyclic Phase 3
21 Anesthetics, Dissociative Phase 3
22 Adrenergic Agents Phase 3
23 Antidepressive Agents Phase 3
24 Analgesics, Non-Narcotic Phase 3
25 Adjuvants, Immunologic Phase 2, Phase 3
26 ferric gluconate Phase 3
27 Iron Supplement Phase 3
28 Liver Extracts Phase 3
29 Pharmaceutical Solutions Phase 3
30 pancreatin Phase 3
31 polysaccharide-K Phase 3
32 Immunosuppressive Agents Phase 2, Phase 3
33 Immunologic Factors Phase 2, Phase 3
34 Alkylating Agents Phase 2, Phase 3
35 Thymoglobulin Phase 2, Phase 3
36
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
37
Gemcitabine Approved Phase 2 95058-81-4 60750
38
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
39
Lenalidomide Approved Phase 1, Phase 2 191732-72-6 216326
40
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
41
Melphalan Approved Phase 2 148-82-3 4053 460612
42
Mesna Approved, Investigational Phase 2 3375-50-6 598
43
Pentostatin Approved, Investigational Phase 2 53910-25-1 40926 439693
44
alemtuzumab Approved, Investigational Phase 2 216503-57-0
45
Leflunomide Approved, Investigational Phase 2 75706-12-6 3899
46
Pembrolizumab Approved Phase 2 1374853-91-4
47
Cytarabine Approved, Investigational Phase 1, Phase 2 147-94-4 6253
48
Azacitidine Approved, Investigational Phase 1, Phase 2 320-67-2 9444
49
Vidarabine Approved, Investigational Phase 2 24356-66-9 32326 21704
50
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743

Interventional clinical trials:

(show top 50) (show all 205)
# Name Status NCT ID Phase Drugs
1 Evaluation of the Immune Response After Vaccination Against Hepatitis B in Patients With Indolent Lymphoproliferative Disorders With no Treatment. Unknown status NCT01698866 Phase 4
2 Quality of Life Related Response to Treatment in Anemic Cancer Patients Receiving Recormon and Efficacy of the Drug Dosage 30,000 IU Once Weekly in Patients With Lymphoproliferative Disorders Completed NCT00776425 Phase 4 Epoetin beta
3 Fludarabine, Cyclophosphamide, Doxorubicin and Rituximab for the Treatment of Post-transplant Lymphoproliferative Disease (PTLD) Completed NCT01088724 Phase 4 fludarabine, cyclophosphamide, doxorubicin, rituximab
4 Cytotoxic T Cell Therapy for Post Transplant Lymphoproliferative Disease: Randomized Controlled Trial in Transplant Recipients Unknown status NCT00033475 Phase 3
5 Evaluation of Plasmatic Levels of Busulfan in Patients Undergoing Hematopoietic Stem Cell Transplantation Unknown status NCT01800643 Phase 2, Phase 3
6 Phase 3 Study of Recombinant Erythropoetin and Adjuvant I.V. Iron Therapy of Anemic Patients With Lymphoproliferative Disorders Completed NCT00145652 Phase 3 Neo-Recormon and Venofer
7 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
8 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
9 The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study Completed NCT00719563 Phase 3 American ginseng
10 The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study Completed NCT00516503 Phase 3 baclofen/amitriptyline/ketamine gel
11 Predictive Value of the "Cytocapacity Test" Following a Single-dose of rHu-G-CSF in Patients With Lymphoproliferative Diseases and High-dose Therapy Completed NCT01085058 Phase 2, Phase 3 lenograstim
12 A Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin Alfa for Cancer Patients With Chemotherapy-Associated Anemia Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
13 Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Allogeneic Hematopoietic Cell Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure of Rituximab Completed NCT03392142 Phase 3
14 Randomized Study for Comparison of Reduced Intensity Conditioning Protocols Containing Either Thymoglobuline or Alemtuzumab in Patients Undergoing Allogeneic Transplant From Voluntary Unrelated Donors Completed NCT00354120 Phase 2, Phase 3 Alentuzumab;Globulina antilinfocitaria
15 A Randomized, Open-Label, Multicenter Study Of Darbepoetin Alfa Administered Once Every Two Weeks (Q2W) Compared With rHuEPO Administered Once Every Week (QW) For The Treatment Of Anemia In Subjects With Non-Myeloid Malignancies Receiving Multiple Chemotherapy Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
16 A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer Completed NCT00058331 Phase 3
17 A Double-Blind Study Of Nutritional Intervention For The Treatment Of Cancer Cachexia Using Juven® Nutritional Supplement Completed NCT00053053 Phase 3
18 Open-label Extension Study With Tadekinig Alfa (r-hIL-18BP) to Monitor Safety and Tolerability in Patients With IL-18 Driven Monogenic Autoinflammatory Conditions: NLRC4 Mutation and XIAP Deficiency Recruiting NCT03512314 Phase 3 Tadekinig alfa
19 Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure of Rituximab or Rituximab and Chemotherapy Recruiting NCT03394365 Phase 3
20 Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal Trial With Tadekinig Alfa (r-hIL-18BP) in Patients With IL-18 Driven Monogenic Autoinflammatory Conditions: NLRC4 Mutation and XIAP Deficiency Recruiting NCT03113760 Phase 3 Tadekinig alfa
21 Phase III Multicenter Open-label Randomized Clinical Trial Comparing Everolimus and Low Dose Tacrolimus to Tacrolimus and Mycophenolate Mofetil at 6 mo Post-Transplant to Prevent Long-term Complications After Pediatric Heart Transplantation Active, not recruiting NCT03386539 Phase 3 Everolimus;Tacrolimus;Mycophenolate Mofetil
22 In-vivo T-cell Depletion and Hematopoietic Stem Cell Transplantation for Life-Threatening Immune Deficiencies and Histiocytic Disorders Terminated NCT00176826 Phase 2, Phase 3 Myeloablative conditioning regimen
23 Phase II Trial of Rituximab in Patients With B-Cell Lymphoproliferative Disorders Associated With Pharmacologic Immunosuppression Unknown status NCT00003716 Phase 2
24 A Non-randomized, Open-label, Phase II Study of Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) Not Suitable for Transplantation Unknown status NCT03373019 Phase 2 Chidamide combined with R-GDP
25 An Evaluation of the Toxicity and Therapeutic Effects of Epstein-Barr Virus-Immune T-Lymphocytes Derived From a Normal HLA-Compatible or Haplotype-Matched Donor in the Treatment of EBV-Associated Lymphoproliferative Diseases or Malignancies and Patients With Detectable Circulating Levels of EBV DNA Who Are at High Risk for EBV-Associated Lymphoproliferative Diseases Completed NCT00002663 Phase 1, Phase 2
26 A Phase II Study of the Therapeutic Effects Of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies Completed NCT01498484 Phase 2
27 Treatment of T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders With Alemtuzumab (Campath) Completed NCT00345345 Phase 2
28 Open Label Multicenter Study of Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs) Completed NCT01610180 Phase 2 Eltrombopag Olamine
29 A Multicenter Phase II Study Of BMS 247550 (Epothilone B Analogue) In Indolent Lymphoproliferative Disorders Completed NCT00052572 Phase 2 ixabepilone
30 Phase II Study of PS-341 in Low Grade Lymphoproliferative Disorders Completed NCT00023764 Phase 2 bortezomib
31 A Pilot Study of the Combination of Retinoic Acid and Interferon-Alpha2a for the Treatment of Lymphoproliferative Disorders in Children With Immunodeficiency Syndromes Completed NCT00001438 Phase 2 all-trans-retinoic acid with IFN-alpha2a
32 A Phase II Study of the Novel Proteasome Inhibitor Bortezomib in Combination With Rituximab, Cyclophosphamide and Prednisone in Patients With Relapsed/Refractory Indolent B-Cell Lymphoproliferative Disorders and Mantle Cell Lymphoma (MCL) Completed NCT00295932 Phase 1, Phase 2 bortezomib;cyclophosphamide;prednisone
33 A Phase I/II Study: Zevalin Radioimmunotherapy for Patients With Post Transplant Lymphoproliferative Disease Following Solid Organ Transplantation Completed NCT00064246 Phase 1, Phase 2
34 Phase II Study of Cyclophosphamide, Prednisone and Rituximab (CPR) in Children, Adolescents and Young Adults With B-lymphocyte Antigen CD20 (CD20) Positive Post-Transplant Lymphoproliferative Disease (PTLD) Following Solid Organ Transplantation (SOT) Completed NCT00066469 Phase 2 cyclophosphamide;methylprednisolone;prednisone
35 Treatment of Patients With Posttransplant Lymphoproliferative Disorder (PTLD) With a Sequential Treatment Consisting of Anti-CD20 Antibody Rituximab and CHOP+GCSF Chemotherapy (PTLD-1/3) Completed NCT00590447 Phase 2 rituximab monotherapy;sequential R-CHOP
36 A Phase I/II Study of the Histone Deacetylase (HDAC) Inhibitor LBH589 (Panobinostat) in Combination With mTOR Inhibitor RAD001 (Everolimus) in Patients With Relapsed Multiple Myeloma or Lymphoma Completed NCT00918333 Phase 1, Phase 2 panobinostat;everolimus
37 Donor NK Cell Infusion for Progression/Recurrence of Underlying Malignant Disorders After HLA-haploidentical HCT - a Phase 1-2 Study Completed NCT00823524 Phase 1, Phase 2
38 A Phase II Trial of Reduced Intensity Allogeneic Stem Cell Transplantation With Fludarabine, Melphalan and Low Dose Total Body Irradiation Completed NCT01529827 Phase 2 fludarabine phosphate;melphalan;tacrolimus;mycophenolate mofetil;methotrexate
39 Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing Matched Unrelated Donor Stem Cell Transplantation Completed NCT00516152 Phase 2 Busulfan/Fludarabine phosphate/Tacrolimus/Methotrexate/G-CSF
40 Bortezomib Plus Rituximab for EBV + Post Transplant Lymphoproliferative Disease (PTLD) Completed NCT01058239 Phase 2 bortezomib;rituximab
41 A Phase II Study to Evaluate the Efficacy of Posttransplant Cyclophosphamide for Prevention of Chronic Graft-versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation Completed NCT01427881 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;busulfan
42 High-dose Busulfan, High-dose Cyclophosphamide, and Allogeneic Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndromes, Multiple Myeloma and Lymphoma Completed NCT01177371 Phase 2 busulfan;cyclophosphamide;methylprednisolone;methotrexate;cyclosporine
43 Addition of Pre- and Post-Transplant Rituximab for Patients Undergoing Non-myeloablative Allogeneic Hematopoietic Cell Transplantation With Relapsed or Refractory CD20+ B-Cell Malignancies Completed NCT00867529 Phase 2
44 A Phase I/II Clinical Trial of the mTor Inhibitor RAD001 (Everolimus) in Combination With Lenalidomide (Revlimid) for Patients With Relapsed or Refractory Lymphoid Malignancy Completed NCT01075321 Phase 1, Phase 2 everolimus;lenalidomide
45 CD-34 Selection for Ex-vivo T-Cell Depletion of Mobilized Peripheral Blood Stem Cells for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts Receiving Intensive Conditioning Completed NCT00368355 Phase 2 Ara-C;Cyclophosphamide
46 Pilot Study of Prophylactic Dose-Escalation Donor Lymphocyte Infusion After T Cell Depleted Allogeneic Stem Cell Transplant in High Risk Patients With Hematologic Malignancies Completed NCT01839916 Phase 2
47 A Pilot Trial of Vorinostat Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease Following Unrelated Donor Hematopoietic Stem Cell Transplantation Completed NCT01789255 Phase 2 vorinostat;tacrolimus;cyclosporine;methotrexate
48 RC05CB A Pilot, Randomized Comparison of Standard Weekly Epoetin Alfa to Every-3-Week-Epoetin Alfa and Every 3-Week Darbepoetin Alfa Completed NCT00416624 Phase 2 darbepoetin alfa;epoetin alfa
49 Assessment of Early and Standard Intervention With Procrit® (Epoetin Alfa) 120,000 Units Once Every Three Weeks (Q3W) in Patients With Cancer Receiving Chemotherapy Completed NCT00255749 Phase 2
50 Allogeneic Hematopoietic Stem Cell Transplant for Patients With Immunologic or Histiocytic Disorders Using a Non-Myeloablative Preparative Regimen to Achieve Stable Mixed Chimerism Completed NCT00176865 Phase 2 Fludarabine;Melphalan;Anti-thymocyte globulin (ATG);Campath 1H;Cyclosporin A;Mycophenolate mofetil;Intravenous immunoglobulin (IVIG)

Search NIH Clinical Center for Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of Childhood

Cochrane evidence based reviews: lymphoproliferative disorders

Genetic Tests for Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of...

Anatomical Context for Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of...

MalaCards organs/tissues related to Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of Childhood:

40
T Cells, Liver, Bone Marrow, Bone, Breast, Skin, Myeloid

Publications for Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of...

Articles related to Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of Childhood:

# Title Authors PMID Year
1
Haploidentical peripheral blood stem cell transplantation with posttransplant cyclophosphamide for systemic Epstein-Barr virus-positive T-cell lymphoma of childhood. 61
33692531 2021
2
Systemic Epstein-Barr virus-positive T-cell lymphoma of childhood. 61
31886782 2019
3
Systemic Epstein-Barr Virus-positive T-Cell Lymphoma of Childhood Presentation With Hemophagocytosis. 61
30870386 2019
4
Young adult onset systemic Epstein-Barr virus-positive T-cell lymphoproliferative disorders of childhood. 61
26062673 2015
5
Hydroa vacciniforme-like lymphoma: a chronic EBV+ lymphoproliferative disorder with risk to develop a systemic lymphoma. 61
23982171 2013

Variations for Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of...

Expression for Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of...

Search GEO for disease gene expression data for Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of Childhood.

Pathways for Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of...

Pathways related to Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of Childhood according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.44 SH2D1A NCAM1 GZMB CD2
2 10.86 NCAM1 GZMB

GO Terms for Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of...

Cellular components related to Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of Childhood according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasmic stress granule GO:0010494 8.62 TIA1 DDX3X

Biological processes related to Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of Childhood according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 apoptotic process GO:0006915 9.46 TIA1 GZMB DDX3X CD2
2 viral entry into host cell GO:0046718 9.26 NCAM1 CR2
3 protein localization to cytoplasmic stress granule GO:1903608 8.96 TIA1 DDX3X
4 negative regulation of translation GO:0017148 8.8 TIA1 GZMB DDX3X

Molecular functions related to Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of Childhood according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 virus receptor activity GO:0001618 8.96 NCAM1 CR2
2 poly(A) binding GO:0008143 8.62 TIA1 DDX3X

Sources for Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of...

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....